Fred Turner

Fred Turner sells a strange product: health insurance you are encouraged to use early and often, with no copay waiting at the door and no deductible to clear first. Curative, the company he founded in 2020 and leads as CEO, asks new members to do one odd thing - book a baseline visit with a care navigator in the first 120 days. Do it, and your costs for in-network care drop to zero. Skip it, and the plan starts to look like every other plan.

That single mechanic explains why he keeps quoting a number that sounds made up. Curative reports a 98% member engagement rate, in an industry where getting people to read their own benefits packet counts as a win. Turner did not arrive at insurance through actuarial tables. He arrived through a PCR machine, a herd of cattle, and a pandemic.

The logic is the kind of thing that sounds glib until you sit with it. Most insurers make money when care is rationed. Turner's bet is the inverse: spend early on prevention, keep members healthy, and the expensive end of medicine - the hospital stay, the late diagnosis - never arrives. It is a wager on incentives, dressed up as a wager on kindness.

At 17, Turner wanted to know which gene gave his brother red hair. So he built a PCR machine - the device that copies DNA - to go find out. The project won him the UK's Young Engineer of the Year Award. Two years later, in 2013, he was ranked first in the European Union Contest for Young Scientists and listed among the Science Council's top 100 practicing scientists in the UK. He was still a teenager.

He went to Oxford to read biochemistry and left before finishing. The decision was not a stumble. By his own account it was a calculation about speed.

In San Francisco he founded TL Biolabs, a company that did genetic testing - for cattle. Breeders want to know which calves carry which traits, and Turner built the tests to tell them. The Thiel Foundation backed it. Cattle genetics is not where most healthcare founders begin, which is exactly the point: the through-line in his career is not a market, it is a method. Find a measurable biological question, build the instrument that answers it, then chase wherever the answer leads.

TL Biolabs became Shield Bio, and the questions got more human: fast diagnostics for gonorrhea and sepsis. Andreessen Horowitz and Y Combinator backed it, and the tests reached more than 10,000 patients. Then Shield wound down, and Turner started Curative, initially aimed at improving sepsis outcomes.

Then March 2020 happened. Turner pivoted Curative into COVID-19 testing in a matter of weeks, building around a self-collected oral fluid swab and scaling into one of the largest testing operations in the United States. Cities ran public testing programs on his infrastructure. It was, briefly, one of the defining companies of the pandemic.

The harder decision came when demand for testing fell. A weaker founder would have ridden the COVID business down. Turner wound it down instead and rebuilt Curative as a health insurer - the boldest pivot of the lot, because it meant trading a known, shrinking market for an enormous, entrenched one. He kept the lab muscle, the operational speed, and the willingness to start over, and pointed all of it at the deductible.

Ask Turner about his own temperament and he does not reach for a humblebrag. He says he is not particularly patient, and that he likes to press into what actually determines how long a thing takes. That impatience is a feature in a founder who has now reinvented the same company three times. It is also why his advice to other builders sounds less like strategy and more like triage.

Turner talks through the Oxford exit, the pivots, and what he thinks insurance gets backwards in this interview.

▶ Fred Turner: Disrupting Healthcare, Dropping Out of Oxford & Building Curative (YouTube)